Clint A. Stalnecker

Nov 12, 2024 | nature.com | Alvaro Curiel-Garcia |Margo I Orlen |Clint A. Stalnecker |Julien Dilly |Marie C. Hasselluhn |Stephanie Chang | +16 more

Correction to: Nature https://doi.org/10.1038/s41586-024-07379-z Published online 8 April 2024In the version of the article initially published, in the Data availability section, the GEO accession number was incorrect and has now been amended to GSE252002 in the HTML and PDF version of the article.

Jun 6, 2024 | science.org | Benjamin Hale |Jennifer E. Klomp |Clint A. Stalnecker |Jeffrey A. Klomp

Research ArticleCANCERJeffrey A. Klomp https://orcid.org/0000-0002-5243-6987 [email protected], Jennifer E. Klomp https://orcid.org/0000-0003-1781-648X, [...] , Clint A. Stalnecker https://orcid.org/0000-0002-0570-4416, Kirsten L. Bryant https://orcid.org/0000-0003-4026-0942, [...] , A. Cole Edwards, Kristina Drizyte-Miller https://orcid.org/0000-0001-7049-2934, Priya S. Hibshman, J. Nathaniel Diehl https://orcid.org/0000-0002-7309-0903, Ye S. Lee https://orcid.org/0000-0001-9026-6192, [...] , Alexis J.

Apr 8, 2024 | nature.com | Alvaro Curiel-Garcia |Margo I Orlen |Clint A. Stalnecker |Julien Dilly |Marie C. Hasselluhn |Stephanie Chang | +16 more

AbstractBroad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by RAS mutations1,2. RMC-7977 is a highly selective inhibitor of the active GTP-bound forms of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants (RAS(ON) multi-selective)3.

Jul 20, 2023 | cell.com | Clint A. Stalnecker |Channing J. Der

use a systems biology approach to unravel a paradoxical role of microRNA in oncogenic KrasG12D regulation of gene and protein expression. In this issue of Molecular Cell, Shui et al.use a systems biology approach to unravel a paradoxical role of microRNA in oncogenic Krasregulation of gene and protein expression.